Skip to content

About us
CYCLOPS
News
Products
Co-development
Vacancies
Contact

About us
CYCLOPS
News
Products
Co-development
Vacancies
Contact

Cyclops®

Convenient
Reliable
Easy-to-use
Easy-to-carry
Hygienic
Less Cough

About us
CYCLOPS
News
Products
Co-development
Vacancies
Contact

About us
CYCLOPS
News
Products
Co-development
Vacancies
Contact

Characterization and Formulation of Isoniazid for High-Dose Dry Powder Inhalation

I. Sibum, P. Hagedoorn, H.W. Frijlink, F. Grasmeijer

International Journal of Pharmaceutics,
2019,
11 (5)
(DOI: 10.3390/pharmaceutics11050233)

SHARE THIS POST

Recent Posts

Colistin Cyclops® Gains EMA and FDA Orphan Drug Status in Cystic Fibrosis

CYCLOPS® Dry Powder Inhaler Now Available Nationwide in the Netherlands Thanks to Agreement Between Fagron and PureIMS

International Congress of Parkinson’s Disease and Movement Disorders 2024 – poster on Levodopa Cyclops®

Cyclops® in Inhalation Technology magazine!

PureIMS gears up for abbreviated registration of Levodopa Cyclops® against OFF episodes in Parkinson’s disease with the successful completion of a comparative pharmacokinetic study

PureIMS winning the LIFE Science Innovation Award!

PureIMS initiates dose-finding study with Levodopa Cyclops™ dry powder inhaler

PureIMS secures new investment round to develop lead inhalation product and facilitate partnering activities

PureIMS names Frank Lambert to advance commercialization of its Cyclops™ Dry Powder Inhaler (DPI)

Drug Delivery to the Lungs (DDL) poster on Epinephrine Cyclops™

Categories

Categories

Press release (14)
Publication (3)
Scientific publication (6)
Status update (3)

Contact Us

Ceintuurbaan Noord 152
9301 NZ Roden
The Netherlands
T: +31 (0)50 – 2053 325
F: +31 (0)50 – 2053 326
E: info@pureims.com

Social media

Linkedin-in Youtube

Inspiration by Patients

© 2024 pureims